NK cells from malignant pleural effusions are potent antitumor effectors A clue for adoptive immunotherapy

OncoImmunology

Volumn 2, Issue 4, 2013, Pages

  Vacca, Paola ^a   Martini, Stefania ^b   Mingari, Maria C ^a,b   Moretta, Lorenzo ^a,c  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c G GASLINI INSTITUTE   (Italy)

Author keywords

Cancer; Immune response; Immunotherapy; NK cells; Tumor immunology

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; CD94 ANTIGEN; GAMMA INTERFERON; GRANZYME A; GRANZYME B; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; KYNURENINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CELL DAMAGE; CELL FUNCTION; CELL HOMING; CELL INFILTRATION; CELL LOSS; CYTOKINE RELEASE; CYTOLYSIS; DEGRANULATION; EFFECTOR CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTRACELLULAR SIGNALING; LEUKEMIA; NATURAL KILLER CELL; NONHUMAN; PLEURA EFFUSION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REGULATORY MECHANISM; SOLID TUMOR; TUMOR CELL; TUMOR GROWTH; TUMOR LOCALIZATION;

EID: 84886944083     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.23638     Document Type: Article

References (10)

1. Caligiuri MA. Human natural killer cells. Blood 2008; 112:461-9; PMID:18650461; http://dx.doi.org/10.1182/blood-2007-09-077438
2. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001; 19:197-223; PMID:11244035; http://dx.doi.org/10.1146/annurev.immunol.19.1.197
3. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, et al. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 1996; 14:619-48; PMID:8717527; http://dx.doi.org/10.1146/annurev.immunol.14.1.619
4. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29:235-71; PMID:21219185; http://dx.doi.org/10.1146/annurevimmunol-031210-101324
5. Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 2011; 121:3609-22; PMID:21841316; http://dx.doi.org/10.1172/JCI45816
6. Moretta L, Locatelli F, Pende D, Marcenaro E, Mingari MC, Moretta A. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood 2011; 117:764-71; PMID:20889923; http://dx.doi.org/10.1182/blood-2010-08-264085
7. Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, Petretto A, et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res 2012; 72:1407-15; PMID:22258454; http://dx.doi.org/10.1158/0008-5472.CAN-11-2544
8. Balsamo M, Scordamaglia F, Pietra G, Manzini C, Cantoni C, Boitano M, et al. Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc Natl Acad Sci U S A 2009; 106:20847-52; PMID:19934056; http://dx.doi.org/10.1073/pnas.0906481106
9. Vacca P, Martini S, Garelli V, Passalacqua G, Moretta L, Mingari MC. NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation. Eur J Immunol 2012; PMID:23192659
10. Coventry BJ, Ashdown ML. The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses. Cancer Manag Res 2012; 4:215-21; PMID:22904643; http://dx.doi.org/10.2147/CMAR.S33979